Clear cell renal cell carcinoma (ccRCC) is a malignancy that exhibits metabolic reprogramming as a result of genetic mutations. This reprogramming accommodates the energy and anabolic needs of the cancer cells, leading to changes in glucose, lipid, and bio-oxidative metabolism, and in some cases, the amino acid metabolism. Recent evidence suggests that ccRCC may be classified as a metabolic disease. The metabolic alterations provide potential targets for novel therapeutic interventions or biomarkers for monitoring tumor growth and prognosis. This literature review summarized recent discoveries of metabolic alterations in ccRCC, including changes in glucose, lipid, and amino acid metabolism. The development of metabolic drugs targeting these metabolic pathways was also discussed, such as HIF-2α inhibitors, fatty acid synthase (FAS) inhibitors, glutaminase (GLS) inhibitors, indoleamine 2,3-dioxygenase (IDO) inhibitors, and arginine depletion. Future trends in drug development are proposed, including the use of combination therapies and personalized medicine approaches. In conclusion, this review provides a comprehensive overview of the metabolic alterations in ccRCC and highlights the potential for developing new treatments for this disease.
Frontiers in endocrinology. 2023 Jun 06*** epublish ***
Haiyan Zhu, Xin Wang, Shihao Lu, Kongbo Ou
Department of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China., Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China., Orthopaedics, Changzheng Hospital Affiliated to Second Military Medical University, Shanghai, China., Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China.